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IntRoductIon
Prostate cancer is the most frequently diagnosed malignancy 
and one of the leading causes of cancer death in men 
worldwide.[1] In Africa, an estimated pooled incidence rate of 
22.0/100,000 men has been reported.[2] In Nigeria, prostate 
cancer is the most common cancer of men, with an incidence 
of 19.1/100,000 men from the combined Ibadan and Abuja 
Cancer Registries reports of 2010.[3]
A n d r o g e n  d e p r i v a t i o n  t h e r a p y  ( A D T )  i s  t h e 
recommended first-line therapy for advanced prostate 
adenocarcinoma.[4] First-line ADT can be achieved through 
bilateral total or subcapsular orchidectomy (surgical 
orchidectomy) or through the repeated administration of 
gonadotropin-releasing hormone analogs or antagonists (medical 
orchidectomy).[5] The addition of antiandrogens (steroidal or 
nonsteroidal) to orchidectomy (surgical or medical) targets to 
block the effects of adrenal and other extra-testicular androgens 
on the malignant acinar cells, thereby ensuring maximal 
androgen blockade.[6,7]
Androgens are physiologic anabolic hormones. Therefore, 
ADT is accompanied by several adverse effects such as fatigue, 
functional decline, increased body fat, and loss of lean body 
tissue.[8] Other adverse effects of ADT are increased insulin 
resistance, decreased libido and sexual dysfunction, hot 
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flashes, gynecomastia, reduced testis size, anemia, and loss of 
bone mineral density.[9] These effects result from a reduction 
in circulating levels of androgens, mostly testosterone.[10,11] 
ADT is known to impair physical strength with time, resulting 
in increased fatigue.[12] Clearly, ADT has the potential of 
negatively affecting the overall quality of life (QoL) of prostate 
adenocarcinoma patients.
In Nigeria, ADT, in the form of surgical orchidectomy 
is prevalently administered due to a combination of 
late presentation with advanced diseases and challenges 
in accessing medical orchidectomy.[5,13] Although 90% 
disease remission rates have been reported with ADT, the 
aforementioned adverse effects could lead to reduced physical 
wellbeing.
Studies have reported extensively on the benefits of exercise, 
especially supervised exercise, in cancer patients during 
treatment and afterwards.[14] In a systematic review, Gardner 
et al. demonstrated benefits, to prostate adenocarcinoma 
patients, of aerobic and resistance training exercises on 
muscular strength, cardiorespiratory fitness, functional task 
performance, lean body mass, and on level of fatigue, but 
with some inconsistent effects on adiposity.[15] Supervised 
controlled exercise programs are reportedly safe as adjuvant 
therapy in ADT for prostate cancer.[16] When complied with, 
exercise programs, which may be group-based or home-based, 
have been found to significantly improve ADT-related fatigue, 
metabolic and cardiovascular side effects, as well as cognitive 
function.[17]
Do prescribed exercise programs offer additional benefits in 
the care of patients on ADT in our setting? The objective of 
this study, therefore, is to examine the effect of prescribed, 
clinic-based physical exercise program on muscle function, 
cardiopulmonary function, and fatigue in patients on ADT for 
prostate adenocarcinoma in our low-income setting.
 subjects and Methods
Consecutive patients diagnosed with advanced prostate 
adenocarcinoma who have been on ADT for a period of 12 
months form the study population. The patients were recruited 
from the Urology Clinic of a tertiary health institution in 
a low-income setting, while the prescribed exercise was 
undertaken at the Physiotherapy department of the same 
institution. All patients were 12 months post bilateral total 
orchiectomy at recruitment. On enrollment, these patients 
were observed for 6 weeks as control arm before cross over 
to participate in the exercise program for the next 6 weeks.
The cardiopulmonary function was tested with a graded 
exercise test using a modified Young Men’s Christian 
Association (YMCA) protocol for bicycle ergometer. The 
Karvonen formula using the age-predicted maximum heart rate 
and the resting heart rate was used to calculate the safe target 
heart rate zone. Each patient cycled on a bicycle ergometer 
with an inbuilt heart rate monitor regulated by the set age, 
height, and weight of the participant. The resistance on the 
bicycle was increased every 3 min by increasing the wattage to 
achieve 70% of the calculated target heart rate, or the subject 
reached a steady-state heart rate, or until signs of fatigue or 
exhaustion were noted according to the YMCA protocol and 
the American College of Sports Medicine guidelines.[18] Borg’s 
scale was used to determine the patient’s perceived extent of 
exhaustion. Cycling was at subject’s pace as against the 50 
rev/min of the YMCA protocol. The initial wattage was set at 
25 watts, and the machine self-adjusted to maintain the preset 
target heart rate. Maximum oxygen uptake, peak expiratory 
flow rate (PEFR), and exercise duration were determined.
Muscle strength (MS) and endurance were assessed using 
the Oxford technique, where the 10R max was determined 
on a multi-gym resistive exercise machine. Participants were 
guided on how to lift weight safely through the full range in 
the correct form. Weights were lifted incrementally until the 
highest weight that could be lifted without muscle fatigue was 
found. This was judged by determining the weight that could 
be lifted ten times through full range without quivering of the 
muscle. When determined, each participant lifted 80% of their 
maximal weight progressively, starting with 8 repetitions in 
3 sets.
Blood pressure and resting heart rates were measured after 
at least 5 min rest upon arrival for the commencement of 
the exercise activity of the day. Anthropometric measures 
were done with a standard tape rule and a stadiometer with a 
weighing scale attached.
Cardiopulmonary and anthropometric indices as well as brief 
fatigue inventory (BFI) were taken at the onset of the program 
and again at the end of the 6 weeks. A self-report on the change 
in daily activities was used to assess QoL qualitatively. It was 
done by asking simple questions such as, “are you able to cope 
with your daily activities” and “if yes, has it changed for better 
or worse in the last 7 days?”
Ethical clearance was obtained from the Health Research 
Ethics Committee of the University of Nigeria Teaching 
Hospital, Enugu.
Table 1: Observed changes in cardiopulmonary function 
and muscular function parameters
Parameter Mean observed change (%)
Cardiopulmonary function
Maximum oxygen uptake +34
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Results
Of the 34 study subjects that were recruited with informed 
consent,  only 5 completed  the prescribed exercise regimen. 
The subjects that opted out cited logistics associated with a 
thrice weekly visit to the hospital’s physiotherapy unit as the 
main reason. Hence, this is a case series of the 5 men. The mean 
age is 72.2 ± 3.9 years, and the mean body weight is 54 ± 8.9 
kg. They are all 12 months post bilateral total orchidectomy 
at recruitment. 
Table 1 shows the mean changes in cardiopulmonary and 
muscular function parameters. This table shows some positive 
change (improvement) in all parameters of interest except 
in “pull-down” MS. The positive change (improvement) in 
exercise duration is quite remarkable.
The observations from the peak expiratory flow rate (PEFR) 
for each of the participants are shown in Table 2. In all five 
subjects, there is an observable improvement in peak expiratory 
flow rate (PEFR) after the 6 weeks of prescribed controlled 
exercise. The improvement appears to be higher in subjects 
with poorer PEFR pre-exercise.
The duration tolerated per exercise session for each participant 
is noted. Table 3 shows the duration tolerated at the first exercise 
session and the duration tolerated at the last exercise session, 
6 weeks after, for each study participant. Each subject tolerated 
the exercise longer at the conclusion of the 6-week program.
The mean weights tolerated for the various MS and endurance 
exercises at the first exercise session are compared against the 
mean weights tolerated at the last exercise session 6 weeks 
after, as shown in Table 4.
With the exception of pull-down exercise, there is an increase 
in the mean weight tolerated for all the other exercise programs 
over the 6-week period.
All patients reported an improvement in daily activities and 
overall QoL. There is also a mean improvement of 29% in the 
BFI, as shown in Table 5.
At the conclusion of the 6-week exercise program, each subject 
reported an improvement in the BFI ranging from 20% to 45%.
dIscussIon
ADT is generally recognized as the first-line treatment for 
advanced prostate adenocarcinoma.[4] ADT has recognized 
time dependent adverse effects consequent on withdrawing the 
anabolic effect of androgens. Beyond the first few years of ADT, 
and in the absence of any chemical, radiological, or clinical 
evidence of tumor progression, the adverse effects of ADT 
may become major contributors to poor QoL.[9,17] For instance, 
osteoporosis complicating prolonged ADT is known to be a cause 
of spinal adverse events in prostate adenocarcinoma patients.
The beneficial effects of prescribed exercise programs on 
cardiopulmonary function, muscle function, and bone density 
are known and have been leveraged upon in mitigating some 
of the adverse effects of cancer treatment generally.[14,19] 
Hence, the observed poor compliance with prescribed exercise 
program for the prostate adenocarcinoma patients on ADT 
in this low-income setting is quite worrisome. Whatever the 
reasons for this observation may be, the implication is that 
these patients fail to appreciate the suggested possible benefits 
from such exercise programs.
This study investigated the effect of a 6-week supervised, 
clinic-based exercise program for men on ADT of 12 months 
duration for prostate adenocarcinoma. These men are in clinical 
and biochemical remission. The study noted improvement in 
cardiopulmonary function and MS at the least on short-term 
basis, as has been observed from other studies.[19] Though 
these study participants are peasant farmers and traders in 
low-income settings, and cannot be said to have sedentary 
lifestyles, there are observed improvements on the study 
parameters [Table 1] suggesting that activities of daily living 
alone do not constitute adequate physical activity for optimal 
cardiopulmonary and muscular functions in these individuals.[5]
The mean PEFR of these participants prior to the commencement 
of the exercise program is 275.0 L/min [Table 2], which is 
Table 2: Peak expiratory flow rate values before and after 6 weeks of prescribed controlled exercises
Participant ID Preexercise (L/min) Postexercise (L/min) Interval change (L/min) Percentage change
001 236 430 194 82.2
002 233 330 97 41.6
003 243 310 67 27.5
004 363 436 73 20.1
005 300 310 10 3.3
Mean 275.0 363.2 88.2 34.9
Table 3: Compares the tolerated duration of the first 
exercise session at the onset of the exercise program 
and at the conclusion of the exercise program, 6 weeks 











001 10.0 30.0 20.0 200
002 10.0 20.0 10.0 100
003 5.0 20.0 15.0 150 
004 10.0 20.0 10.0 100
005 10.0 20.0 10.0 100
Mean 9.0 22.0 13.0 130
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similar to values observed from studies recruiting elderly 
men with compromised respiratory function, but lower than 
values among men with optimal respiratory function.[17,20] With 
the prescribed exercise program, the mean PEFR increased 
appreciably, approaching optimal values in men. Interestingly, 
the increment in PEFR is seen more among participants with 
poorer PEFR values at recruitment [Table 2]. The implication, 
therefore, is that PEFR may, with further evaluation, be used as 
a possible indicator of patients that will benefit from prescribed 
exercise programs during ADT.
At the end of the 6 weeks, each participant lasted longer 
at exercise sessions when compared to the values at the 
onset [Table 3]. In addition, there is some improvement in 
MS of each participant, as observed with the various exercise 
modules [Table 4]. These observations are indicators of 
increased ability to perform physical functions with less fatigue 
and an improved sense of well-being. Fatigue is documented as 
one of the challenges of therapy for cancer and active measures 
are required to modify it.[18] Supervised exercises constitute a 
recognized part of such active measures.
At recruitment, the participants in this study checked in 
moderate to severe fatigue with the BFI [Table 5]. On the 
background of nadir levels of serum testosterone and serum 
prostate-specific antigen, tumor burden may be contributing 
minimally to the level of fatigue reported than at recruitment. 
The ongoing ADT may be contributing substantially to the 
observed fatigue.[12] That the exercise-related improvement 
in MS at the end of the 6-week program coincides with a 
reduction in the reported level of fatigue is in keeping with 
the recommendation that supervised exercise be instituted 
during ADT.[19,21]
In addition, a 29% reduction in the mean reported level of 
BFI is observed, possibly because the exercise program 
is for 6 weeks. There is no reason to adduce that longer 
durations of exercise will not result in higher values of 
reduction in BFI since observations elsewhere suggest that 
improvement in muscle function, as well as cardiopulmonary 
and cognitive function, with controlled exercises, correlates 
positively with the duration of the patient with the exercise 
program.[22]
Findings from this series suggest that patients on ADT in the 
form of bilateral total orchidectomy in low socioeconomic 
settings benefit from prescribed physical exercise programs. 
Compliance with such prescriptions, however, could be a major 
challenge. Undertaking prescribed exercises beyond activities 
of daily living improves cardiopulmonary function and level 
of fatigue with activities of daily living. This study is limited 
by high drop out rates of participants due to the need to visit 
the hospital physiotherapy unit frequently.
conclusIons
Prescribed exercise programs comprising aerobic and resistive 
components are beneficial in improving cardiopulmonary and 
muscle function with resultant improvement in the reported 
level of fatigue among persons diagnosed with advanced 
prostate adenocarcinoma who are in remission on ADT. It 
appears persons with poorer PEFR benefit more from such 
exercise programs.   A properly funded randomized control 
trial is needed to further evaluate the findings thereof.
Acknowledgment
The authors are grateful to Ahmad R. Adamu, Emelie M. 
Anekwu, and David A. Okoh for their contribution to the 
production of this manuscript.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
RefeRences
1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, 
Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, 
regional, and national cancer incidence, mortality, years of life lost, 
years lived with disability, and disability-adjusted life-years for 29 
Table 4: Compares the mean weights tolerated at the first exercise session against the mean weights tolerated at the 
last exercise session
Muscle strength and 
endurance exercise








Pull-up 6.75 7.65 0.90 13.3
Pull-down 11.25 11.25 0.0 0.0
Chest press 6.75 7.65 0.90 13.3
Leg extension 7.65 8.55 0.90 11.7
Leg curl 1.80 2.25 0.45 25.0
Table 5: The brief fatigue inventory before and after the 
exercise program is shown for each of the 5 participants
Participant 
ID
Preexercise Postexercise Change Percentage 
change
001 85 65 −20 23.5
002 81 65 −16 19.7
003 82 60 −22 26.8
004 60 33 −27 45.0
005 64 44 −20 31.2
Mean 74.4 53.4 −21.0 29.2
Nigerian Journal of Medicine ¦ Volume 29 ¦ Issue 4 ¦ October-December 2020564
Chigbo, et al.: Improving qoL during ADT in prostate cancer
cancer groups, 1990 to 2016: A systematic analysis for the global burden 
of disease study. JAMA Oncol 2018;4:1553-68.
2. Adeloye D, David RA, Aderemi AV, Iseolorunkanmi A, Oyedokun A, 
Iweala EE, et al. An estimate of the incidence of prostate cancer in Africa: 
A systematic review and meta-analysis. PLoS One 2016;11:e0153496.
3. Jedy-Agba E, Curado MP, Ogunbiyi O, Oga E, Fabowale T, Igbinoba F, 
et al. Cancer incidence in Nigeria: A report from population-based 
cancer registries. Cancer Epidemiol 2012;36:e271-8.
4. Yassin A, Al Rumaihi K, Alzubaidi R, Alkadhi S, Al Ansari A. 
Testosterone, testosterone therapy and prostate cancer. Aging Male 
2019;7:1-9.
5. Badmus TA, Adesunkanmi AR, Yusuf BM, Oseni GO, Eziyi AK, 
Bakare TI, et al. Burden of prostate cancer in southwestern Nigeria. 
Urology 2010;76:412-6.
6. Wu Y, Tang L, Azabdaftari G, Pop E, Smith GJ. Adrenal androgens 
rescue prostatic dihydrotestosterone production and growth of prostate 
cancer cells after castration. Mol Cell Endocrinol 2019;486:79-88.
7. Hejmej A, Bilinska B. The effects of Flutamide on cell-cell junctions in 
the testis, epididymis and prostate. Reprod Toxicol 2018;81:1-16.
8. Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, 
Keating NL, et al. Adverse effects of androgen deprivation therapy and 
strategies to mitigate them. Eur Urol 2015;67:825-36.
9. Kim DK, Lee JY, Kim KJ, Hong N, Kim JW, Hah YS, et al. Effect 
of Androgen-Deprivation Therapy on Bone Mineral Density in Patients 
with Prostate Cancer: A Systematic Review and Meta-Analysis. J Clin 
Med 2019;18:113.
10. Sayyid RK, Sayyid AK, Klaassen Z, Fadaak K, Goldberg H, 
Chandrasekar T, et al. Testosterone responders to continuous androgen 
deprivation therapy show considerable variations in testosterone levels 
on follow up: Implications for clinical practice. J Urol 2018;199:251-6.
11. Kang M, Lee S, Oh JJ, Hong SK, Lee SE, Byun SS. Surgical castration 
effectively delays the time of starting a systemic chemotherapy in 
castration-resistant prostate cancer patients refractory to initial androgen 
deprivation therapy. Prostate Int 2015;3:123-6.
12. Alibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, 
Tannock I, et al. Impact of androgen-deprivation therapy on physical 
function and quality of life in men with nonmetastatic prostate cancer. 
J Clin Oncol 2010;28:5038-45.
13. Fatunmbi M, Saunders A, Chugani B, Echeazu I, Masika M, Edge S, 
et al. Cancer registration in resource-limited environments – Experience 
in Lagos Nigeria. J Surg Res 2019;235:167-70.
14. Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in 
prostate cancer patients: A systematic review of randomized controlled 
trials. Support Care Cancer 2012;20:221-33.
15. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on 
treatment-related adverse effects for patients with prostate cancer 
receiving androgen-deprivation therapy: A systematic review. J Clin 
Oncol 2014;32:335-46.
16. Wall BA, Galvão DA, Fatehee N, Taaffe DR, Spry N, Joseph D, et al. 
Maximal exercise testing of men with prostate cancer being treated with 
androgen deprivation therapy. Med Sci Sports Exerc 2014;46:2210-5.
17. Holmes SJ, Allen SC, Roberts HC. Relationship between lung function 
and grip strength in older hospitalized patients: A pilot study. Int J Chron 
Obstruct Pulmon Dis 2017;12:1207-12.
18. Bossi P, Di Pede P, Guglielmo M, Granata R, Alfieri S, Iacovelli NA, 
et al. Prevalence of fatigue in head and neck cancer survivors. Ann Otol 
Rhinol Laryngol 2019;128:413-9.
19. Ahmadi H, Daneshmand S. Androgen deprivation therapy: 
Evidence-based management of side effects. BJU Int 2013;111:543-8.
20. Scheeren CF, Gonçalves JJ. Comparative evaluation of ventilatory 
function through pre and postoperative peak expiratory flow in patients 
submitted to elective upper abdominal surgery. Rev Col Bras Cir 
2016;43:165-70.
21. Cormie P, Zopf EM. Exercise medicine for the management of androgen 
deprivation therapy-related side effects in prostate cancer. Urol Oncol 
2020;38:62-70.
22. Langelier DM, D’Silva A, Shank J, Grant C, Bridel W, Culos-Reed SN. 
Exercise interventions and their effect masculinity, body image, and 
personal identity in prostate cancer – A systematic qualitative review. 
Psychooncology 2019;28:1184-96.
Nigerian Journal of Medicine ¦ Volume 29 ¦ Issue 4 ¦ October-December 2020 565
